{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:42:23Z","timestamp":1784608943279,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2008339"],"award-info":[{"award-number":["GNT2008339"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002337","name":"Petre Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jneuroim.2025.578715","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:20:56Z","timestamp":1754450456000},"page":"578715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structural and functional biomarkers of visual dysfunction in MOG antibody-positive optic neuritis: a scoping review"],"prefix":"10.1016","volume":"408","author":[{"given":"Fiona","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Brilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578715_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105864","article-title":"Optical coherence tomography angiography measurements in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease: a systematic review and meta-analysis","volume":"91","author":"Amanollahi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"Asseyer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578715_bb0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1212\/01.WNL.0000094315.19931.90","article-title":"Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite","volume":"61","author":"Balcer","year":"2003","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.jneuroim.2025.578715_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/brain\/awu335","article-title":"Vision and vision-related outcome measures in multiple sclerosis","volume":"138","author":"Balcer","year":"2015","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578715_bb0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578715_bb0035","article-title":"Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"7","author":"Barnes","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578715_bb0040","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103525","article-title":"OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS","volume":"58","author":"Chen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578715_bb0060","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578715_bb0065","first-page":"1017","article-title":"The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic neuritis treatment trial","volume":"41","author":"Cole","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578715_bb0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/1352458508091367","article-title":"Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography","volume":"14","author":"Costello","year":"2008","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578715_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/19714009221124308","article-title":"MRI pattern in acute optic neuritis: comparing multiple sclerosis, NMO and MOGAD","volume":"36","author":"Darakdjian","year":"2023","journal-title":"Neuroradiol. J."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578715_bb0080","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458520937281","article-title":"Visual field loss and structure-function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody","volume":"27","author":"Deschamps","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673472","article-title":"Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0100","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1038\/s41598-022-19848-4","article-title":"Structure-function correlates of vision loss in neuromyelitis optica spectrum disorders","volume":"12","author":"Gigengack","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40942-020-00262-9","article-title":"A practical guide to optical coherence tomography angiography interpretation","volume":"6","author":"Greig","year":"2020","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0110","article-title":"A single-center retrospective series of OCT and MRI findings in pediatric MOGAD optic neuritis patients","author":"Guniganti","year":"2024","journal-title":"Can. J. Ophthalmol."},{"issue":"7758","key":"10.1016\/j.jneuroim.2025.578715_bb0115","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0140-6736(72)91155-5","article-title":"Delayed visual evoked response in optic neuritis","volume":"1","author":"Halliday","year":"1972","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578715_bb0120","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ophtha.2023.05.024","article-title":"Predictors of poor visual outcome in myelin oligodendrocyte glycoprotein-related optic neuritis","volume":"130","author":"Handzic","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0125","article-title":"Radiologic predictors of visual outcome in myelin oligodendrocyte glycoprotein-related optic neuritis","author":"Handzic","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","article-title":"Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?","volume":"18","author":"Havla","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0140","series-title":"Clinical Decisions in Glaucoma","first-page":"52","author":"Hodapp","year":"1993"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578715_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archopht.1993.01090020085029","article-title":"Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group","volume":"111","author":"Keltner","year":"1993","journal-title":"Arch. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578715_bb0150","first-page":"59","article-title":"Importance of Muller cells","volume":"5","author":"Kobat","year":"2020","journal-title":"Beyoglu Eye J."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578715_bb0155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0165-5728(84)90064-X","article-title":"A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody","volume":"6","author":"Linnington","year":"1984","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578715_bb0160","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1212\/CPJ.0000000000000187","article-title":"The application of optical coherence tomography in neurologic diseases","volume":"5","author":"Maldonado","year":"2015","journal-title":"Neurol. Clin. Pract."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578715_bb0165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578715_bb0170","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1756285616655264","article-title":"Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders","volume":"9","author":"Martinez-Lapiscina","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578715_bib301","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","article-title":"Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis","volume":"39","author":"Matsuda","year":"2015","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00415-024-12803-5","article-title":"Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision","volume":"272","author":"Nicolescu","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578715_bb0185","first-page":"362","article-title":"Aging and low-contrast vision: face perception","volume":"21","author":"Owsley","year":"1981","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0190","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105857","article-title":"Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography","volume":"91","author":"Peng","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578715_bb0200","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578715_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102718","article-title":"Anti-MOG associated disorder-clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience","volume":"48","author":"Rempe","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578715_bb0215","article-title":"The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis","volume":"7","author":"Roca-Fernandez","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578715_bb0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/WNO.0000000000002124","article-title":"Myelin oligodendrocyte glycoprotein antibody disease optic neuritis: a structure-function paradox?","volume":"44","author":"Ross","year":"2024","journal-title":"J. Neuroophthalmol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578715_bb0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/WNO.0000000000000421","article-title":"20\/40 or better visual acuity after optic neuritis: not as good as we once thought?","volume":"36","author":"Sabadia","year":"2016","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2377-14-31","article-title":"Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis","volume":"14","author":"Schinzel","year":"2014","journal-title":"BMC Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578715_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","volume":"96","author":"Schwake","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578715_bb0240","doi-asserted-by":"crossref","first-page":"4015075","DOI":"10.1155\/2019\/4015075","article-title":"Different characteristics of Aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China","volume":"2019","author":"Song","year":"2019","journal-title":"J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578715_bb0245","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578715_bb0255","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/01658107.2023.2287518","article-title":"Clinical features and prognostic factors in anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"48","author":"Takai","year":"2024","journal-title":"Neuroophthalmology"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0260","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578715_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123362","article-title":"Meta-regression of optic nerve imaging and visual outcome in myelin oligodendrocyte glycoprotein antibody optic neuritis","volume":"468","author":"Tao","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578715_bb0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0280","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00415-020-10097-x","article-title":"Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis","volume":"268","author":"Vicini","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578715_bb0285","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/j.1538-9235.1993.tb03071.x","article-title":"Visual requirements for reading","volume":"70","author":"Whittaker","year":"1993","journal-title":"Optom. Vis. Sci."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578715_bb0290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/iovs.61.6.40","article-title":"Relationship between acuity and contrast sensitivity: differences due to eye disease","volume":"61","author":"Xiong","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578715_bb0295","doi-asserted-by":"crossref","first-page":"503","DOI":"10.21037\/qims.2019.03.03","article-title":"Neuroanatomical substrates underlying contrast sensitivity","volume":"9","author":"Yang","year":"2019","journal-title":"Quant. Imaging Med. Surg."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578715_bb0300","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1167\/iovs.11-7434","article-title":"Latency delay of visual evoked potential is a real measurement of demyelination in a rat model of optic neuritis","volume":"52","author":"You","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2025.578715_bib302","doi-asserted-by":"crossref","first-page":"105518","DOI":"10.1016\/j.msard.2024.105518","article-title":"Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: The importance of age of onset and prognosis-related radiological features","volume":"85","author":"Zhao","year":"2024","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:33:37Z","timestamp":1782261217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825001961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"alternative-id":["S0165572825001961"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578715","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and functional biomarkers of visual dysfunction in MOG antibody-positive optic neuritis: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578715"}}